Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(4.58)
# 191
Out of 5,182 analysts
26
Total ratings
59.26%
Success rate
38.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CING Cingulate | Maintains: Buy | $16 → $14 | $6.14 | +128.01% | 5 | Mar 23, 2026 | |
| CRVO CervoMed | Maintains: Buy | $19 → $11 | $4.14 | +165.70% | 5 | Mar 18, 2026 | |
| NRSN NeuroSense Therapeutics | Initiates: Buy | $3 | $0.83 | +261.45% | 1 | Mar 10, 2026 | |
| OVID Ovid Therapeutics | Initiates: Buy | $3 | $2.20 | +36.36% | 1 | Dec 11, 2025 | |
| PYPD PolyPid | Maintains: Buy | $10 → $9 | $4.39 | +105.01% | 3 | Nov 13, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $12 → $13 | $32.11 | -59.51% | 3 | Nov 12, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $140 → $60 | $0.72 | +8,233.33% | 2 | Aug 18, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $1.07 | +180.37% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $1.85 | +224.32% | 3 | Aug 13, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $13.15 | +120.53% | 1 | Dec 5, 2024 |
Cingulate
Mar 23, 2026
Maintains: Buy
Price Target: $16 → $14
Current: $6.14
Upside: +128.01%
CervoMed
Mar 18, 2026
Maintains: Buy
Price Target: $19 → $11
Current: $4.14
Upside: +165.70%
NeuroSense Therapeutics
Mar 10, 2026
Initiates: Buy
Price Target: $3
Current: $0.83
Upside: +261.45%
Ovid Therapeutics
Dec 11, 2025
Initiates: Buy
Price Target: $3
Current: $2.20
Upside: +36.36%
PolyPid
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $4.39
Upside: +105.01%
Capricor Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $32.11
Upside: -59.51%
Reviva Pharmaceuticals Holdings
Aug 18, 2025
Reiterates: Buy
Price Target: $140 → $60
Current: $0.72
Upside: +8,233.33%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $1.07
Upside: +180.37%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $1.85
Upside: +224.32%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $13.15
Upside: +120.53%